Part C: Agency Budget Statements — ANSTO
Australian Nuclear Science and Technology Organisation — Appropriations 2001-02 Table 1.1: Appropriations and other revenue ($’000)
Outcome Departmental (price of outputs) Administered
|
Revenue from Government
|
Revenue
|
Price of
|
Annual appropriations
|
Special
|
Total
|
Total
|
|
(appropriations)
|
from other sources(4)
|
outputs(3)
|
($'000)
|
approps
|
administered appropriations
|
appropriations
|
|
Bill No. 1 Total Special
|
|
|
Bill No. 1 Bill No. 2
|
|
|
|
|
approps
|
|
|
(SPPs &
|
|
|
|
|
|
|
|
NAOs)(2)
|
|
|
|
|
(A) (B) (C = A+B)
|
(D)
|
(E = C+D)
|
(F) (G)
|
(H)
|
(I = F+G+H)
|
(J=C+I)
|
Outcome 1
|
15,954 15,954
|
|
15,954
|
|
|
|
15,954
|
Nuclear-based Infrastructure
|
(C1) (1) *100%
|
|
(E1)(1)
|
|
|
|
|
Outcome 2
|
786
|
|
786
|
|
786
|
|
|
|
|
786
|
Disposition of Spent
|
|
|
(C2)(1)
|
|
(E2)(1)
|
|
|
|
|
|
Fuel
|
|
|
*100%
|
|
|
|
|
|
|
|
Outcome 3
|
|
|
113,884
|
33,201
|
147,085
|
|
|
|
|
113,884
|
Science and Technology
|
113,884
|
|
(C3)(1)
|
|
(E3)(1)
|
|
|
|
|
|
Solutions
|
|
|
*77.4%
|
|
|
|
|
|
|
|
Total
|
130,624
|
0
|
(K1) 130,624
|
33,201
|
163,825
|
0
|
0
|
0
|
0
|
130,624
|
The amounts in shading are included in annual appropriation bills
|
|
Departmental capital (equity injections and loans)
|
|
(K2) 91,019
|
|
|
Administered capital
|
|
0
|
|
|
Total appropriations
|
|
221,643
|
-
Note: C1 and E1 refer to information provided in Table 2.1.1; C2 and E2 refer to information provided in Table 2.1.2; C3 and E3 refer to information provided in Table 2.1.3. Amount K1 refers to Budgeted Statement of Financial Performance (Table 3.1) and amount K2 refers to Capital Budget (Table 3.4).
-
Under the appropriation structure, Bill No. 2 includes Specific Purpose Payments (SPP’s), New Agency Outcomes (NAO’s), administered capital and departmental capital via departmental injections and loans.
-
Refer to Budgeted Statement of Financial Performance for application of agency revenue.
-
Revenue from other sources includes other revenue from government (eg resources free of charge) and revenue from other sources (eg sales of goods and services). Non-appropriated departmental revenues are detailed in Appendix 1.
* Percentage figures indicate the percentage contribution of Revenue from Government (Departmental Appropriations) to the Total Price of Outputs, by outcome.
173
BUDGET MEASURES — SUMMARY
Table 1.2: Summary of Measures disclosed in the 2001-02 Budget
Measure
|
Outcome
|
Output groups affected
|
Appropriations budget Admin Dept expenses outputs Total 2001-02 ($'000)
|
Appropriations estimate Admin Dept expenses outputs Total 2002-03 ($'000)
|
Appropriations estimate Admin Dept expenses outputs Total 2003-04 ($'000)
|
Appropriations estimate Admin Dept expenses outputs Total 2004-05 ($'000)
|
Output Pricing Review of Australian Nuclear Science and Technology Organisation
|
3
|
3.1 3.5 3.6
|
8,400
|
8,400
|
9,300
|
9,300
|
9,400
|
9,400
|
8,900
|
8,900
|
ADMINISTERED CAPITAL AND DEPARTMENTAL EQUITY INJECTIONS AND LOANS
ANSTO will receive an equity injection to fund the construction of a replacement research reactor at Lucas Heights. The expenditure and drawdown is shown in the Capital Budget Statement (see Table 3.4).
174
Section 2: Outcomes and outputs information
OUTCOMES AND OUTPUTS
The map on the following page shows the relationship between outcomes and the contributing outputs of ANSTO’s activities.
Outcome 1 financial details by output appear in Table 2.1.1, while non-financial information appears in Table 2.2.1.
Outcome 2 financial details by output appear in Table 2.1.2, while non-financial information appears in Table 2.2.2.
Outcome 3 financial details by output appear in Table 2.1.3, while non-financial information appears in Table 2.2.3.
The following graph illustrates the allocation of resources across the three ANSTO outcomes in 2001-02.
Graph 1: Departmental appropriation by outcome 2001-02
Outcome 1 $15.954m
Outcome 2 (12.2%) $0.786m (0.6%)
Outcome 3 $113.884m (87.2%)
Australian Nuclear Science and Technology Organisation
Chief Executive, Professor Helen Garnett
Outcomes and outputs
Total Price of Outputs $163.825m Departmental Outcomes Appropriation $130.624m Equity Injection $91.019m
Output 1.1
|
Output 2.1
|
Output 3.1
|
Output 3.2
|
Output 3.3
|
Output 3.4
|
Output 3.5
|
Output 3.6
|
Effective contract
|
A program of
|
Management of
|
Expert scientific
|
The acquisition of
|
Science and
|
Regular production
|
The exploitation of
|
management for the
|
shipments for
|
core nuclear
|
and technical
|
knowledge, through
|
technology services
|
and sale of
|
ANSTO’s intellectual
|
design and
|
reprocessing of all
|
facilities, providing
|
services for, and on
|
research, and its
|
to industry and the
|
radiopharma
|
and physical assets
|
construction of the
|
HIFAR spent fuel in
|
Australia with
|
behalf of,
|
utilisation, through
|
Australian research
|
ceuticals and
|
|
replacement
|
place
|
nuclear capability
|
Government in
|
innovation, to
|
and development
|
radioisotopes for
|
|
research reactor
|
|
and credibility from
|
support of
|
advance the
|
community,
|
medical and
|
|
|
|
which socio
|
Australia’s national
|
beneficial
|
including training of
|
industrial
|
|
|
|
economic benefits
|
and international
|
applications of
|
students in nuclear
|
applications and
|
|
|
|
flow to Australia,
|
strategic and
|
nuclear science and
|
science and
|
other services,
|
|
|
|
the R&D community
|
nuclear policy
|
technology to
|
technology and its
|
through designated
|
|
|
|
and industry
|
objectives
|
problems of
|
applications
|
business units
|
|
|
|
|
|
environmental,
|
|
|
|
|
|
|
|
medical, social and
|
|
|
|
|
|
|
|
industrial
|
|
|
|
|
|
|
|
importance
|
|
|
|
Total Price
|
Total Price
|
Total Price
|
Total Price
|
Total Price
|
Total Price
|
Total Price
|
Total Price $1.907m
|
$15.954m
|
$0.786m
|
$58.101m
|
$9.356m
|
$50.350m
|
$6.597m
|
$20.774m
|
Approp $-2.527m
|
Approp $15.954m
|
Approp $0.786m
|
Approp $57.355m
|
Approp $9.036m
|
Approp $48.084m
|
Approp $2.045m
|
Approp $-0.109m
|
|
Equity Injection
|
|
Equity Injection
|
|
|
|
|
|
$86.019m
|
|
$5.000m**
|
|
|
|
|
|
**$5.0m equity injection approved for the year 2000-01 being funded by injection in year 2001-02.
176
Dostları ilə paylaş: |